Biotechnology company Cartography Biosciences Inc announced on Tuesday that it has entered a multi-year collaboration with biopharmaceutical company Pfizer Inc (NYSE:PFE) to discover tumour-selective antigens.

Under the agreement, Cartography will apply its ATLAS and SUMMIT platforms to identify and validate antigens in an undisclosed oncology indication. Pfizer may opt-in on multiple antigens and will lead all research, development, and commercialisation for selected programmes.

Cartography's lead programme, CBI-1214, will remain wholly owned and independently advanced.

The ATLAS and SUMMIT platforms analyse antigen expression across healthy and tumour cell states to identify targets with optimal tumour selectivity.

Cartography is eligible to receive up to USD65m in upfront, near-term milestone, and option exercise payments. The collaboration carries a potential total value exceeding USD850m, including future development, regulatory, commercial milestones, as well as tiered royalties on net sales.